CORONA Remedies Ltd.
2,022.80+43.4 (+2.19%)
9 Jul, 3:30 PM
Income Statement
Abridged
Understanding Income Statement
CORONA Remedies Ltd. income statement covering revenue, operating profit, EBITDA, PAT and EPS across annual and quarterly periods.
Balance Sheet
Abridged
Understanding Balance Sheet
CORONA Remedies Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.
Cash Flow
Abridged
Understanding Cash Flow Statement
CORONA Remedies Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.
Business Segment Analysis
FY End:
Mar 26
CORONA Remedies Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.
Capex
Pharmaceuticals (100.0%)₹ 174.13 Cr
Revenue / Sales
Pharmaceuticals (100.0%)₹ 1,403.18 Cr
Assets
Pharmaceuticals (100.0%)₹ 1,205.14 Cr
Operating Income
Pharmaceuticals (100.0%)₹ 256.30 Cr
Regional Segment Analysis
FY End:
Mar 26
CORONA Remedies Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.
Revenue / Sales
India (98.0%)₹ 2,749.45 CrOutside India (2.0%)₹ 56.91 Cr
Historical Segment Analysis
Track how CORONA Remedies Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.
Business
Frequently Asked Questions
What is the revenue of CORONA Remedies Ltd.?
The latest trailing twelve month revenue of CORONA Remedies Ltd. is ₹ 1,403.18 Cr, reflecting a 1-year growth of 17.28% and a 3-year CAGR of 16.65%. Annual and quarterly revenue trends are available in the Income Statement section.
What is the net profit of CORONA Remedies Ltd.?
The latest trailing twelve month net profit (PAT) of CORONA Remedies Ltd. is ₹ 185.12 Cr, with a 3-year earnings CAGR of 29.66%. Detailed profit history across annual and quarterly periods is in the Income Statement section.
What is the EBITDA of CORONA Remedies Ltd.?
The trailing twelve month EBITDA of CORONA Remedies Ltd. is approximately ₹ 255.57 Cr (based on an operating margin of 18.21%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.
What is the EPS of CORONA Remedies Ltd.?
The trailing twelve month Earnings Per Share (EPS) of CORONA Remedies Ltd. is 30.27. EPS trends across annual and quarterly periods are visible in the Income Statement section.
What is the debt level of CORONA Remedies Ltd.?
The debt-to-equity ratio of CORONA Remedies Ltd. stands at 0.22. The interest coverage ratio is 36.67x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.
What is the book value per share of CORONA Remedies Ltd.?
The estimated book value per share of CORONA Remedies Ltd. is 124.79 (derived from a P/B ratio of 16.21 and market price of ₹ 2,022.80), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.
What is the cash flow from operations of CORONA Remedies Ltd.?
The trailing twelve month operating cash flow of CORONA Remedies Ltd. is ₹ 229.15 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.
Does CORONA Remedies Ltd. report consolidated or standalone financials?
CORONA Remedies Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.